Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Pharma Decries Govt's Latest No-Deal Brexit Planning

Executive Summary

The provision of “express” freight capacity for medicines that need to be delivered urgently is among the latest proposals from the UK government to help cope with supply disruptions in the event of a no-deal Brexit. But the biopharmaceutical industry says some of the proposals are too short notice and will place additional burdens on companies.

You may also be interested in...



UK Names Ferry Firms To Carry No-Deal Brexit Medicine Supplies

Ferry and other transport operators are to bring thousands of heavy goods vehicles a week to the UK carrying life-saving medicines and other supplies if the UK leaves the EU without a deal. However, the ferries will not use the standard cross-Channel ports, which are expected to become heavily congested in a no-deal scenario.

Brexit Stakes Rise As New UK Prime Minister Takes Over

The UK has a new prime minister in Boris Johnson, who is likely to surround himself with strongly pro-Brexit ministers. The life sciences industry will need to continue lobbying for its interests to be protected in the event of a no-deal exit.

A New Definition: The EU Answer To Medicines Shortages?

What is a medicines shortage? The answer may seem obvious, but the fact that European regulators have only now come up with a commonly agreed definition suggests otherwise.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS125540

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel